

1. This District Court has jurisdiction over the subject matter of the above action and has personal jurisdiction over the parties.
2. As used in this Consent Judgment, (i) the term “Apotex Product” shall mean a drug product sold, offered for sale or distributed pursuant to Abbreviated New Drug

Application No. 211730 (and defined in greater detail in the Settlement Agreement); and (ii) the term “Affiliate” shall mean, with respect to a Party, any entity or person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such Party. For purposes of this definition, “control” means (a) ownership, directly or through one or more intermediaries, of (i) more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or (ii) more than fifty percent (50%) of the equity interests in the case of any other type of legal entity or status as a general partner in any partnership, or (b) any other arrangement whereby an entity or person has the right to elect a majority of the board of directors or equivalent governing body of a corporation or other entity or the right to direct the management and policies of a corporation or other entity.

3. Except as specifically authorized pursuant to the Settlement Agreement, Apotex, including any of its Affiliates, successors and assigns, is enjoined from infringing United States Patent Numbers 6,774,122, 7,456,160, 8,329,680 and 8,466,139, on its own part or through any Affiliate, by making, having made, using, selling, offering to sell, importing or distributing of the Apotex Product.

4. Compliance with this Consent Judgment may be enforced by AstraZeneca and Apotex and their successors in interest, or assigns, as permitted by the terms of the Settlement Agreement.

5. This Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and the Settlement Agreement.

6. All claims, counterclaims, affirmative defenses and demands in this action are hereby dismissed with prejudice and without costs, disbursements or attorneys' fees to any party.



Renee Marie Bumb, U.S.D.J.

We hereby consent to the form and entry of this Order:

s/ John E. Flaherty

John E. Flaherty
Ravin R. Patel
McCARTER & ENGLISH LLP
Four Gateway Center
100 Mulberry Street
Newark, NJ 07102
(973) 622-4444

s/ Arnold B. Calmann

Arnold B. Calmann
Katherine A. Escanlar
Saiber LLC
One Gateway Center,
10th Floor, Suite 1000
Newark, New Jersey 07102
Tel: (973) 622-3333

*Attorneys for AstraZeneca AB, AstraZeneca
UK Limited, and AstraZeneca
Pharmaceuticals LP*

Attorneys for Apotex Inc. and Apotex Corp.